REGENERON PHARMACEUTICALS's ticker is and the CUSIP is 75886F907. A total of 6 filers reported holding REGENERON PHARMACEUTICALS in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $902,000 | -49.6% | 2,400 | -40.0% | 0.06% | -65.1% |
| Q3 2017 | $1,788,000 | -53.3% | 4,000 | -48.7% | 0.17% | +14.5% |
| Q2 2017 | $3,831,000 | -62.1% | 7,800 | -70.1% | 0.14% | +98.6% |
| Q1 2017 | $10,114,000 | -45.1% | 26,100 | -48.0% | 0.07% | -14.1% |
| Q4 2016 | $18,428,000 | -9.9% | 50,200 | -1.4% | 0.08% | -13.3% |
| Q3 2016 | $20,463,000 | -0.7% | 50,900 | -13.7% | 0.10% | +1.0% |
| Q2 2016 | $20,605,000 | -6.3% | 59,000 | -3.3% | 0.10% | -8.5% |
| Q1 2016 | $21,987,000 | +8.9% | 61,000 | +64.0% | 0.11% | +8.2% |
| Q4 2015 | $20,195,000 | -59.0% | 37,200 | -64.9% | 0.10% | -52.0% |
| Q3 2015 | $49,305,000 | +224.3% | 106,000 | +255.7% | 0.20% | +200.0% |
| Q2 2015 | $15,202,000 | +8.6% | 29,800 | -3.9% | 0.07% | +7.9% |
| Q1 2015 | $13,996,000 | -23.5% | 31,000 | -30.5% | 0.06% | -14.9% |
| Q4 2014 | $18,297,000 | +36.4% | 44,600 | +19.9% | 0.07% | +34.5% |
| Q3 2014 | $13,411,000 | -5.0% | 37,200 | -25.6% | 0.06% | -14.1% |
| Q2 2014 | $14,124,000 | -15.6% | 50,000 | -10.2% | 0.06% | -9.9% |
| Q1 2014 | $16,726,000 | +3.2% | 55,700 | -5.4% | 0.07% | +22.4% |
| Q4 2013 | $16,212,000 | -3.0% | 58,900 | +10.3% | 0.06% | -1.7% |
| Q3 2013 | $16,707,000 | +77.7% | 53,400 | +27.8% | 0.06% | +73.5% |
| Q2 2013 | $9,400,000 | – | 41,800 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 2,137 | $48,057,000 | 3.21% |
| KNIGHT CAPITAL GROUP LLC | 15,600 | $3,508,000 | 0.06% |
| Citadel Advisors | 118,000 | $26,536,000 | 0.05% |
| Timber Hill LLC | 41,800 | $9,400,000 | 0.03% |
| Calamos Advisors LLC | 430 | $3,197,000 | 0.02% |